New immunotherapy option for High-Risk pancreatic cancer patients
Disease control
AVAILABLE
This expanded access program offers ELI-002 7P, an immunotherapy, to pancreatic cancer patients with specific KRAS or NRAS gene mutations who have had their tumor removed but are at high risk of the cancer coming back. The treatment aims to stimulate the immune system to target a…
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 16, 2026 23:38 UTC